Collaborating partners

Our research group collaborates with the Eudragene project, a European research project in which data and DNA from patients who have experienced rare serious type B reactions are collected. This project aims to investigate genetic determinants of seven specific serious ADRs; Torsade de Pointes associated with long QT syndrome, myopathy/rhabdomyolysis caused by statins or fibrates, agranulocytosis, tendon rupture/tendinitis caused by fluoroquinolones, liver injury, acute psychosis caused by mefloquine, and Stevens-Johnson syndrome. Within the 7th Framework Program, headed by Prof Colin Palmer of the University of Dundee, we also collaborate with several European researchers, focusing on ACE-inhibitor induced angioedema and statin-induced myopathy.

Other collaborators include the US-based International Serious Adverse Event Consortium (iSAEC), which focuses on drug-induced liver injury, serious skin reactions, and bisphosphonate-induced osteonecrosis of the jaw. National collaborators include specialists in rheumatology at Uppsala University Hospital studying the genetic basis of methotrexate-induced liver injury, and specialists in obesity-related disease, which is commonly induced by antidepressants or neuroleptics.

For adverse reactions to Covid19 vaccines, we collaborate with Science for Life Laboratory at Karolinska institutet, and with the Department of Medical Biochemistry and Microbiology at Uppsala University.